Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.77) by 49.02 percent. This is a 13.33 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $265.196 million which beat the analyst consensus estimate of $235.692 million by 12.52 percent. This is a 38.50 percent increase over sales of $191.476 million the same period last year.